 1/3 of all B-ALL cases. A safe and effective treatment capable of targeting CRLF2 B-ALL would have a significant health impact in the United States and in Central and South America where rates of CRLF2 B-ALL are even higher. We have discovered a novel biologic that selectively targets the
1/3 of all B - ALL cases. A safe and effective treatment adequate to of target CRLF2 B - ALL would have a significant health impingement in the United States and in Central and South America where rate of CRLF2 B - ALL are even higher. We have discovered a novel biologic that selectively target the
 1/3 ov all B-ALL cases. A safe xnd effective tteqtment capabme of tafgeting CRLF2 B-ALL would have a signuficant health impact kn the Unpted Statws aid in Central anv South Americz whexe rates of CRLF2 B-ALL are aven higher. We hxvz discovered a novel biologic that sqlectivrlj targets the
1/3 of all B-ALL cases. A safe treatment of targeting B-ALL would have the States and in and South America rates of CRLF2 B-ALL are even We have discovered a novel biologic that selectively targets the
 1/3 of all B-ALL cases. A safe and effEctive treaTment CapAblE oF tarGetiNg CRLF2 B-ALL woulD Have A significant health impaCt in tHe uNiteD stAtes aNd in CenTRaL ANd SOuTh ameRiCA wHere rAteS of CRLF2 b-ALL are eveN hiGhEr. We have discOVeRed a novel bIolOgic that seleCtiVely taRgEts THe
 1/3 of all B-ALL cases. A  safe andeffec tiv e t re atme nt c apable of targ e ting  CRLF2 B-ALL would hav e a s ig n ific a nt  heal th impa c ti n  th eUn ite dS ta tes a ndin Cent ral and So uth  A merica where ra tes of CRL F2B-ALL are ev enhigher .Weh ave d isc overe d a no v el bio logic tha ts electi v ely tar g e ts  the 
 1/3_of all_B-ALL cases. A safe_and effective_treatment_capable of_targeting_CRLF2 B-ALL would_have a significant_health impact in the_United States and_in_Central and South America where rates of CRLF2 B-ALL are even higher. We have_discovered_a novel_biologic_that_selectively targets the